291), has shown to enhance the effect of SMO antagonist LDE-225 in blocking tumour cell proliferation in vitro and tumour growth in vivo and to increase sensitivity to conventional chemotherapy in murine PTCH1 mutant cells and in human MB cell lines (Ref. 292). The gene discussed is SMO; the disease is neoplasm.